In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.
Search results for: biosimilars
Voice of Rheumatology Coalition Meeting: Enhancing Collaboration
The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities that will affect both the practice of rheumatology and patient care in the year ahead. The Coalition, composed of leading rheumatology professional societies and patient advocacy groups, gathered to examine…
The Ethical Tug-of-War Over Biosimilar Adoption
The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…
FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Unless Congress Acts, Medicare Reimbursement Will Remain Flat or Drop in 2025
The 2025 Medicare Physician Fee Schedule final rule, released Nov. 1, includes a conversion factor of $32.3465, a 2.83% drop from 2024. In response to advocacy efforts from the ACR and other medical societies, Congress recently introduced the Medicare Patient Access and Practice Stabilization Act of 2024, which would eliminate the 2.83% payment cut and provide an inflationary update for 2025 equal to 50% of the Medicare Economic Index.
Updates from the ACR Insurance Subcommittee
The ACR Insurance Subcommittee (ISC) of the Committee on Rheumatologic Care has been hard at work, advocating to payers on behalf of the ACR and its members. Following is an update on some of the work this group has been doing to help address concerns about reimbursement and administrative burden, while ensuring continued access to…
ACR Convergence 2024 Preview: Key Business Takeaways
In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.
Spotlight on Pediatric Rheumatology in Singapore
A pioneer of pediatric rheumatology in Singapore, Dr. Elizabeth Ang details her unique clinical experiences.
Affiliate Society Council Active & Reenergized, Reports Chair Gwenesta B. Melton, MD
ASC Chair Gwenesta B. Melton, MD, shares the connections and activities that are helping the council develop stronger ties in and outside the ACR.
How the ACR Helps with Reimbursement, Utilization Management & Other Practice Challenges
Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 32
- Next Page »